

CytoSorbents Corporation

NASDAQ: CTSO

Working to Save Lives Through
Blood Purification

Needham Healthcare Conference
April 12, 2016



Safe Harbor Statement

Statements in this presentation regarding CytoSorbents Corporation and its operating subsidiaries CytoSorbents Medical Inc. and CytoSorbents Europe GmbH that are not historical facts are forward-looking statements and are subject to risks and uncertainties that could cause actual future events or results to differ materially from such statements. Any such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. It is routine for our internal projections and expectations to change. Although these expectations may change, we are under no obligation to inform you if they do. Actual events or results may differ materially from those contained in the projections or forward-looking statements. The following factors, among others, could cause our actual results to differ materially from those described in a forward-looking statement: our history of losses; potential fluctuations in our quarterly and annual results; competition, inability to achieve regulatory approval for our device, technology systems beyond our control and technology-related defects that could affect the companies' products or reputation; risks related to adverse business conditions; our dependence on key employees; competition for qualified personnel; the possible unavailability of financing as and if needed; and risks related to protecting our intellectual property rights or potential infringement of the intellectual property rights of third parties. This list is intended to identify only certain of the principal factors that could cause actual results to differ from those discussed in the forward-looking statements. Readers are referred to a discussion of important risk factors detailed in the Company's Form 10-K filed with the Securities and Exchange Commission on March 9, 2016 and other reports and documents filed from time to time by us, which are available online at www.sec.gov.



CytoSorbents

Working to Save Lives Through Blood Purification

CytoSorbents: A Leader in Critical Care Immunotherapy



Leading the Prevention or Treatment of
Life-Threatening Inflammation
in the ICU and Cardiac Surgery using
CytoSorb® Blood Purification



CytoSorbents At a Glance

- International footprint across two offices
 - Headquarters: Monmouth Junction, NJ
 - Administrative, ISO 13485 manufacturing, QA/QC, R&D
 - Sales Office: Berlin, Germany
- Flagship product, CytoSorb® is E.U. approved, with distribution across 32 countries
- Strategic Partnerships with Fresenius Medical Care and Biocon Ltd
- Strong government support with \$17M+ in grants and contracts
- 60+ employees and consultants
- More than 11,000 human treatments performed safely
- Pursuing U.S. approval of CytoSorb® in cardiac surgery
- Expecting acceleration of growth this year after record 2015 sales of ~\$4M and gross margins of 62%

Leadership Background



Phillip Chan, MD, PhD – Chief Executive Officer and President

Former Partner at the \$80M NJTC Venture Fund, leading life science investments for 5 years. Co-founder of Andrew Technologies, commercializing its HydraSolve™ lipoplasty device in the U.S. MD/PhD from Yale School of Medicine, internal medical residency at the Beth Israel Deaconess Medical Center at Harvard.



Vincent Capponi, MS - Chief Operating Officer

20+ years experience in the medical device, pharmaceutical and imaging fields. Led the first regulatory approval for the heparin flush syringe, used worldwide in hospitals, and managed manufacturing of > 1 million units/week



Kathleen Bloch, MBA, CPA – Chief Financial Officer

20+ years as CFO of private and public companies. Former Laureate Biopharma CFO, a contract biopharmaceutical manufacturer



Robert Bartlett, MD - Chief Medical Officer

World-renowned pioneer of extracorporeal membrane oxygenation therapy (ECMO) – used worldwide in ICUs in refractory lung failure. Former Director of the Surgical Intensive Care Unit at University of Michigan, with extensive experience in cardiothoracic surgery and critical care medicine including the treatment of sepsis



Christian Steiner, MD – Vice President of Sales and Marketing

13+ years experience in sales and marketing of extracorporeal therapy and critical care sales at Teraklin for MARS, the first liver failure dialysis technology, and at Pulsion Medical (hemodynamic monitoring)



Christopher Cramer, MS, MBA – Vice President of Business Development

15+ years experience in business development and commercial experience. Former Senior Director of New Venture Development at Johnson & Johnson, and previously at PwC Consulting



Controlling Deadly Systemic Inflammation







CytoSorbents

Working to Save Lives Through Blood Purification

Severe Inflammation: Deadly in the ICU

Millions worldwide admitted to the intensive care unit annually with deadly inflammatory conditions

Sepsis	ARDS	Burn Injury	Trauma	Pancreatitis	Influenza	Cancer Immunotherapy
						
~27M cases ~10M deaths	~5M cases ~1.5M deaths	~1.5M cases High morbidity	~40M cases ~8M deaths	~0.5M severe cases ~125K deaths	~4M severe cases ~500K deaths	<1M and in Clinical Trials

- Massive inflammation causes cell death and organ failure. Patients are kept alive with “life support” – machines like mechanical ventilation, dialysis, and vasopressors, that do not help them get better, but keep them alive until hopefully the body starts to heal itself
- Because of the lack of effective therapies, approximately 1 in every 3 patients dies
- Staggering costs: Lack of “active” therapies lead to patients lingering days to weeks in the ICU at \$2-3,000 per day in the U.S.¹

Critical care (U.S.): \$80-90B per year² Sepsis: \$20.3B³ Lung failure: \$8.8 billion³ Kidney failure: \$4.7 billion³

¹ Cooper, L, et al, Crit Care Med 2004, 32(11):2247-2253.



² Halpern, NA, et al., Crit Care Med 2010, 38(1):65-71.

³ Torio, CM and Andrews, RM. “National Inpatient Hospital Costs: The Most Expensive Conditions” (2013) Healthcare Cost and Utilization Project (HCUP) and Agency for Healthcare Research and Quality.




Inflammation: Dangerous in Cardiac Surgery

- ~1M Open Heart Surgeries in US and EU annually
 - Coronary artery bypass graft surgery
 - Valve repair or replacement
 - Heart or lung transplantation
 - Congenital defect repair
 - Aortic reconstruction
- Complex cardiac surgeries require extended surgical times on the heart-lung machine, resulting in increased destruction of blood cells, production of toxic free hemoglobin, cytokines, and other inflammatory substances that can trigger severe inflammation
- The result is frequently organ dysfunction and failure, particularly cardiovascular, lung and kidney failure




Cytokines Fuel the Fire of Inflammation

- Cytokines are small proteins that normally help stimulate and regulate the immune system and control inflammation
- Cytokines are a dual edged sword
 - Required for proper immune system function
 - But in mild to moderate excess, cytokines can cause or exacerbate disease (e.g. autoimmune diseases)
- “Cytokine storm”, a vast excess of cytokines, can lead to a massive uncontrolled systemic inflammatory response syndrome (SIRS)



Massive Inflammation Causes Organ Failure

Organ failure of vital organs leads to nearly half of all ICU deaths



Little can be done to prevent or treat it today



CytoSorb® Removes the Fuel to the Fire


- Targets \$20+ billion opportunity in critical care and cardiac surgery
- European Union approved as the only specific cytokine filter for elevated cytokines
- Clinically proven to remove key cytokines in blood of critically-ill patients
- Removes many other inflammatory mediators such as free hemoglobin, bacterial toxins, and bilirubin
- Safe and well-tolerated: In 11,000+ human treatments, most in critically-ill patients and more than 1,000 used during open heart surgery



*CytoSorb is not yet approved in the U.S.

Powerful Blood Purification Technology


CytoSorb is based on biocompatible, highly porous polymer beads that act like tiny sponges to remove harmful substances from blood



- Protected by 32 issued US patents and multiple applications pending
- Manufactured at our ISO 13485 certified facility in New Jersey
- One of the highest grade medical sorbents on the market

CytoSorb[®]: Plug and Play with Existing Machines


Easy to Use, No Special Equipment or Training Required



- Place a temporary dialysis catheter in a major vein
- Connect the device to a standard dialysis machine found in hospitals worldwide
- Pump blood out of the body and through the cartridge
- Polymer beads directly contact blood and remove unwanted or toxic substances
- “Purified” blood is pumped back into the patient
- Able to treat 70+ total blood volumes per 24h treatment
- Each treatment uses a new cartridge




CytoSorb® Active in Cytokine Sweet Spot



CytoSorb[®] Broadly Reduces Cytokines


Cytokine reduction over time during *in vitro* perfusion with serum (or buffer)




The two lines on each graph represent CytoSorb cytokine removal from serum (triangle) or buffer (square)
Valenti, I "Characterization of a Novel Sorbent Polymer for the Treatment of Sepsis" 2008



Goal: Prevent or Treat Organ Failure




Improve
Patient
Outcomes
And
Survival




Decrease
Cost Of
ICU and
Patient
Care

Sepsis



ARDS



Burn Injury



Trauma



Pancreatitis



Influenza



Surgical



The Potential to Revolutionize Critical Care Medicine



CytoSorbents

Working to Save Lives Through Blood Purification

CytoSorb: A New Immunomodulation Strategy to Control Severe Inflammation in the ICU

**Anti-Inflammatory
(too weak)**

NSAIDs

Aspirin

**Anti-cytokine
antibodies**

**Anti-integrin
antibodies**

Anti-oxidants



**Immunosuppressive
(too strong)**

Corticosteroids

Chemotherapy

**Organ transplant
Anti-rejection drugs**

Radiation

**Immune system
ablation**

**Anti-leukocyte
Antibodies**

**Immunomodulatory
("balanced")**




CytoSorbents

Working to Save Lives Through Blood Purification

Case Report: Necrotizing Fasciitis

- A 19-year old man developed a painful infection on his right hand and was rushed to a hospital with high fever and malaise
- Started on broad spectrum antibiotics for a suspected deep infection in the carpal tunnel
- Rapid onset of multi-organ failure with shock, kidney dysfunction and respiratory failure with infection quickly spreading up his arm
- Extensive surgical debridement confirmed beta-hemolytic Streptococcal infection, but conditioned worsened requiring increasing vasopressors and CRRT for kidney failure
- Failing therapy, CytoSorb was started. After first treatment, blood pressure significantly improved and after two treatments, vasopressors were reduced by 90% and IL-6 declined from 2,300 pg/mL to 36 pg/mL



- Renal function returned after the second CytoSorb treatment and mechanical ventilation was weaned 4 days later
- Patient recovered and amputation of his arm was avoided

~\$17 Million in US Government Support

- DARPA awarded \$3.8M five year (2012-present) contract as part of “Dialysis-Like Therapeutics” program to treat sepsis by removing cytokines and pathogen-derived toxins
- U.S. Army awarded ~\$1.2M SBIR contracts for trauma and burn injury research (2011-present)
- U.S. Air Force funding a 30-patient human pilot study (~\$3M) in trauma (2013-present); FDA approved trial
- US Dept of Health and Human Services awarded \$0.5M grant (2010) for therapies that can save lives and reduce costs under the QTDP Program
- NIH grant awarded \$7M five year (2006-2010) to University of Pittsburgh and Dr. John Kellum to research CytoSorb bead for treatment of sepsis
- NIH/NHLBI awarded \$1.7M Phase I & II SBIR contracts to advance HemoDefend purification technology with the goal of improving the quality and safety of blood transfusions (2013- present)
- JPEO-CBD awarded \$150K Phase I SBIR for fungal mycotoxin removal



Drive CytoSorb Revenues

CytoSorb® An Excellent Business Model

- **Huge market**
Sold to hospitals & critical care doctors. Targets “need to have” life-or-death scenarios
- **Little to no competition**
- **Critical care physicians understand the problem**
- **Plug and play, high margin, disposable “razorblade”**
Hospital’s existing hemodialysis infrastructure is the “razor”, no new hardware
- **Technicians already know how to use the device**
- **Hospitals in Germany/Austria pay for the device and then receive reimbursement**
Depending on the application and devices used, revenue potential per patient ~\$1-5K
- **Affordable yet profitable with blended gross margins of 60+%, target > 80%**
- **Highly centralized intensive care units easy for small sales force to access**

Direct Sales: Germany, Austria, Switzerland

CytoSorbents' direct sales force focused on most major university and public hospitals in Germany, Austria and Switzerland. German market alone is \$1.0-1.5 billion



Dr. Christian Steiner, MD
Vice President – Sales and Marketing and General Manager
CytoSorbents Europe GmbH



Stefan M. Baudis
International Sales Director



Dr. Joerg Scheier, MD
European Medical Director



Dr. Volker Humbert, MD
Director – Clinical Affairs



Dominik Gutzler
Head of Product Management



Dr. Rainer Kosanke, PhD
Head of Scientific Marketing



Alexandru Bojan
Business Manager Export



Hans-Juergen Kraus
Regional Sales Manager
Southern Germany



Matthias Hoeldtke
Regional Sales Manager
Southeast Germany



Uwe Gerks
Regional Sales Manager
Northern Germany



Martin Scherer
Regional Sales Manager
Southwest Germany



Andreas Pendleler
Regional Sales Manager
Western Germany



Steffen Martens
Regional Sales Manager
Northeast Germany



Eva Wechsler
Application Specialist



Ilona Otto
Sales Assistant/Customer Support
Direct




Petra Hoffman
Sales Assistant/Customer Support
International




E.U. Approval Opens Global Distribution

Distributed in 32 countries covering 2.1 billion lives.

Expanding to other EU countries and countries outside the EU that accept CE Mark




Quarterly “Euro-Adjusted” Product Sales



Strong Q4 2015 sales driven by 3x direct sales and 2x customers from Q4 2014



Product Sales Growth, “Euro Adjusted”



Potential for Growth Acceleration

- In Germany alone, there are ~154,000 cases of severe sepsis or septic shock each year. Here, we have:
 - ✓ Established reimbursement
 - ✓ Customers including majority of major university and many public hospitals
 - ✓ Significant key opinion leader support
 - ✓ Strong direct sales team and support infrastructure

2,100 acute care hospitals in Germany; top 400 have >400 beds

300-600 sepsis patients per hospital annually


CytoSorb ASP > \$1,000 per cartridge.

\$3,000-5,000 average total CytoSorb treatment cost per patient

If adopted as standard of care, each hospital \approx \$1-3 million for sepsis alone

Growth Driven by Direct, Distributor, Partner Sales

Theoretical Revenue Growth Based on Layering*



* This graph is provided only to demonstrate the concept of revenue layering. It does NOT represent revenue forecasts or guidance


Drive Clinical Data to Support CytoSorb As Standard of Care



CytoSorbents

Working to Save Lives Through Blood Purification

Robust Clinical Program and Team



3rd International CytoSorb Users Meeting



ISICEM 2015

ISICEM News
The official daily newsletter of the 36th ISICEM Tuesday 16 March 2015 Day 1



Welcome to Brussels...

because of the interplay between industry and the clinic, and we want to continue that bond. You begin today, as we always do, with a rich and informative opening session that will be a particular highlight of the program, filled with key lectures, as well as the eagerly-anticipated Report of the Round Table Conference on Recovery after Critical Illness. Held in the expansive yet intimate Henry Le Boef auditorium, it is perhaps the only chance during the four days that we can all sit together to share in several vital topics, so I do look forward to seeing you there. But there is also much more to come, and depending on your specialty, interests or treatment goals, I'm sure there will be plenty of options to stimulate your interest. Finally, I must thank you all for your understanding with regards to the elevated security this year. We do hope it did not cause any inconvenience for you. I wish you a very enjoyable and enlightening meeting, and invite you to join us this evening for the opening cocktail welcome in the scientific exhibition area.

Jean-Louis Vincent
ISICEM Chairman
Professor of intensive care medicine
Digny of Intensive Care, Erasme University Hospital, Université Libre de Bruxelles
President of the World Federation of Societies of Intensive and Critical Care Medicine


As the 2014 edition of the International Symposium on Intensive Care and Emergency Medicine draws to a close, it is with great pleasure that I welcome you to the Square for a comprehensive program packed with the latest and greatest topics in the field. Over the next four days, physicians, nurses, and allied healthcare professionals from all over the world will join together for a fascinating program of lectures, tutorials, workshops, debates, and more, with hundreds of individuals taking to the stage to share their expertise. As always, discussions will center on a multitude of front-line issues, facilitating an open forum in which we can all share the most clinically relevant advances, research developments, therapeutic nuances, and management techniques. Of course, we thank our sponsors for helping make this possible – and we encourage you to spend some time in the scientific exhibition to see the latest medical and scientific equipment, pharmaceutical products, books, and services related to intensive care and emergency medicine. I'd like to see you there, and I hope you'll have a great time.

Hemodynamic monitoring in 2025 3
Paradigm shift for stem cells in sepsis 8
Turning up the HEAT on fever control . . . 12
Ushering in a new era of antibiotic stewardship 18

CytoSorbents **Satellite Symposium**
REGAIN CONTROL in SIRS and Sepsis: New insights into the CytoSorb® Therapy
Thursday, March 17th 2015
12:30pm – 01:30pm, Copper Hall
Cytosorbents
www.cytosorbents.com




CytoSorbents ISICEM Research Symposium



Leading US Advisors in Cardiac Surgery

Dr. Joe Zwischenberger, M.D.
- SAB Chair
University of Kentucky



Dr. Robert Bartlett, M.D.
University of Michigan



Dr. Paul Checchia, M.D.
Texas Children's
Hospital in Houston



Dr. Jonathan William Haft, M.D.
University of Michigan



Dr. Nicholas Smedira, M.D.
Cleveland Clinic Foundation



Dr. Craig Smith, M.D.
Columbia University




Dr. Peter Wearden, M.D., Ph.D.
U. of Pittsburgh Medical Center



REFRESH I Trial Update

REduction in FREe Hemoglobin

- 40-patient, eight-center study evaluating the safety and efficacy of intra-operative use of CytoSorb® in a heart-lung machine during complex cardiac surgery in elective, non-emergent cardiac surgery > 3 hours
 - Aortic reconstruction, CABG redos, multiple valve replacements, etc
- Goal: Safe reduction of plasma-free hemoglobin and other inflammatory mediators that can cause post-operative complications



REFRESH I Trial Update

REduction in FREe Hemoglobin Trial



- Working with major cardiac surgery centers
 - Baylor College of Medicine
 - Baystate Medical Center
 - Columbia University
 - Cooper University Hospital
 - University of Kentucky
 - University of Maryland
 - University of Pennsylvania
 - University of Pittsburgh Medical Center
- 7 of 8 sites currently active in the trial
- Approximately 50% enrolled
- Expected to complete enrollment by mid-2016, to be followed by discussions with FDA on direction for potential pivotal trial (REFRESH 2) intended to support application for U.S. approval of CytoSorb for cardiac surgery



Leading Advisors in Critical Care

John Kellum, MD (Chair)
University of Pittsburgh



Mitchell Cohen, MD
University of San Francisco



Raul Coimbra, MD, PhD
University of San Diego



Ronald Maier, MD
University of Washington, Seattle



Ernest Moore, MD
University of Colorado



Emil Paganini, MD
Cleveland Clinic Foundation



Joseph Parrillo, MD
Hackensack Heart and
Vascular Hospital




Claudio Ronco, MD
St. Bartolo Hospital, Vicenza, Italy



U.S. Trial for Severe Sepsis or Septic Shock

- Sepsis, the overzealous immune response to a serious infection, is a Top Ten cause of death by causing organ injury, organ failure and death
- Largest, most complex, critical care market; 27 million people afflicted worldwide each year, estimated 9 million deaths.
- Currently no approved products to treat sepsis
- U.S. clinical trials planned to advance CytoSorb toward U.S. FDA approval for sepsis



CytoSorbents

Working to Save Lives Through Blood Purification

CytoSorb Attacks Sepsis Broadly



Inflammatory cytokines (organ failure) & other factors



Immunosuppressive cytokines & re-establish immune responsiveness



Many bacterial toxins (organ failure)



Re-establish proper leukocyte trafficking to prevent cell-mediated organ injury



Improvement in hemodynamics



Reduction in capillary leak

No other single therapy has demonstrated this broad range of activity

Refractory Septic Shock

At the 26th Symposium for Intensive Medicine + Critical Care in Bremen, Germany, Dr. Sigrun Friesecke, Senior Intensivist in the Greifswald University Hospital MICU reported on a prospective, single arm study in 22 patients with refractory late-stage septic shock

- Patients had refractory shock despite high doses of vasopressors, respiratory failure requiring mechanical ventilation or ECMO, anuric kidney failure requiring dialysis, and lactate > 8 mmol/L
- A similar population (n=16) receiving standard of care, where shock could not be reversed, also on mechanical ventilation with an initial lactate level of 6.1 ± 4 mmol/L, and 75% requiring renal replacement therapy had a mortality of 100% at 28 days.*
- Results from the CytoSorb Greifswald Study
 - 28-day survival was 41%, a 30-40% absolute improvement over expected (0-10%)
 - Resolution of shock in 68% of patients treated with CytoSorb
 - Reduction of IL-6 from an initial average of 87,000 pg/mL to below 10,000 pg/mL after 24 hours of treatment

* Conrad, M., et. al., "Early prediction of norepinephrine dependency and refractory septic shock with a multimodal approach of vascular failure", J Crit Care, 2015; 30:739-743.

Leverage Pipeline to Establish Strategic Partnerships



Fresenius Medical Care Partnership

- Entered into a multi-year partnership with Fresenius, the world's largest dialysis company, for exclusive distribution of CytoSorb® in critical care in France, Poland, Denmark, Norway, Sweden, and Finland
- CytoSorb® is a key part of Fresenius' growth strategy in critical care
- Fresenius has committed to annual minimum purchases to maintain exclusivity
- Leveraging Fresenius' critical care leadership and industry-leading sales force and distribution
- Potential for broader future synergy and expansion



Fresenius Medical Care and ISICEM

- Fresenius initiated the marketing push behind CytoSorb® at the International Symposium of Intensive Care and Emergency Medicine (ISICEM) Conference in Brussels, Belgium two weeks ago
- CytoSorb® was featured in the Fresenius exhibition booth on the multiFiltrate Acute Therapy System
- Fresenius used the event to introduce the CytoSorb® therapy broadly to its customers
- Fresenius also sent approximately 18 people to our 3rd International CytoSorb Users Meeting



multiFiltrate



Fresenius Medical Care


42



CytoSorbents

Working to Save Lives Through Blood Purification

Biocon Strategic Partnership: Creating the Most Comprehensive Treatment for Sepsis



Treat Primary Infection with
Antibiotics

Treat Massive
Inflammatory Response

- Biocon is the largest biotechnology company in India
- Partnership formed in late 2013
- Significantly growth in India with expansion into Sri Lanka
- Expanded partnership to include co-development and funding of small trials



Cardiac Surgery Partner Update

- Established partnership in France with a top 4 global cardiac surgery company
 - Key clinical data from the cardiac surgery evaluation study led by Prof. Christophe Baufreton, MD, PhD, cardiothoracic surgeon and Vice Dean of Research from C.H.U - Angers, France, in a patient population similar to those in the REFRESH I study, was presented at the 3rd International CytoSorb Users meeting which credited CytoSorb with increased patient stability
- Currently in discussions with multiple cardiac surgery companies
- CytoSorb[®] used safely in more than 1,000 intra-operative cardiac surgery cases in Europe



Polymer Beads: Broad and Valuable Pipeline




Critical Care, High Risk Surgery




Blood Collection & Transfusion

ContrastSorb




CT Imaging, Interventional Radiology

DrugSorb



Drug Overdose, Chemo Removal

BetaSorb



Improving Dialysis

CE Mark Approved

Under Development



CytoSorbents

Working to Save Lives Through Blood Purification

Increase Investor Awareness



NASDAQ Capital Market Listed

- Clean capital structure with good liquidity for investors



Added to Russell Microcap Index

CytoSorbents Corporation Set to Join Russell Microcap Index

6/19/15

CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to reduce deadly uncontrolled inflammation in hospitalized patients around the world, is set to join the Russell Microcap® Index at the conclusion of the Russell indexes annual reconstitution on June 26, 2015, according to a [preliminary list of additions](#) posted on June 12, 2015.

Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

Dr. Phillip Chan, Chief Executive Officer of CytoSorbents stated, "We are pleased to be included in the Russell Microcap Index, a significant corporate achievement that is expected to increase visibility and exposure of our company and life-saving technology to the broader investment community. This complements our continued institutional investor outreach, where the response has been extremely positive to date."

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately \$5.7 trillion in assets are benchmarked to the Russell's U.S. indexes. Russell Indexes are part of FTSE Russell, a leading global index provider.

For more information on the Russell 1000 and the Russell indexes reconstitution, go to "Recon Central"



CytoSorbents

Working to Save Lives Through Blood Purification

June 2015

Increase Institutional Ownership

CytoSorbents™ (NASDAQ: CTSO)

Owner Name	Date	Shares Held	Change (Shares)	Change (%)	Value (in 1,000s)
VANGUARD GROUP INC	12/31/2015	508,063	16,435	3.34	2,398
AMERICAN INTERNATIONAL GROUP INC	12/31/2015	244,045	17,445	7.70	1,152
GEODE CAPITAL MANAGEMENT, LLC	12/31/2015	125,873	(1,673)	(1.31)	594
SKYLANDS CAPITAL, LLC	12/31/2015	52,500	0	0.00	248
CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM	12/31/2015	46,100	0	0.00	218
BLACKROCK FUND ADVISORS	12/31/2015	41,596	1,801	4.53	196
SUSQUEHANNA INTERNATIONAL GROUP, LLP	12/31/2015	32,169	(14,331)	(30.82)	152
BANK OF MONTREAL /CAN/	12/31/2015	27,400	27,400	New	129
BLACKROCK INSTITUTIONAL TRUST COMPANY, N.A.	12/31/2015	26,460	12,391	88.07	125
NORTHERN TRUST CORP	12/31/2015	23,709	0	0.00	112
GOLDMAN SACHS GROUP INC	12/31/2015	22,941	3,691	19.17	108
BLACKSTONE GROUP L.P.	12/31/2015	20,118	20,118	New	95



Increase Analyst Coverage

COMPANY UPDATE

CytoSorbents Corporation (CTSO/ NASDAQ)
February 19, 2015

BREAN CAPITAL, LLC

Jonathan Aschoff, (212) 702-6652
Yi Cheng, (212) 702-6620

jaschoff@breancapital.com
YCheng@breancapital.com

CytoSorb Appears To Us To Be Worth Using To Alleviate CRS After CAR T Therapy

Buy
TP: \$25.00

H.C.WAINWRIGHT&CO.

Target Price Revision
Medical Device
January 27, 2015

CytoSorbents Corp (CTSO)
Rating: Buy

Swayampakula Ramakanth, Ph. D.
212-356-0544
sramakanth@hwcwresearch.com

Expanding Horizons; New \$12 Price Target; Reiterate Buy

Stock Data 01/26/2015 **Exciting year for CytoSorb development. At the end of 2014,**

Zacks Small-Cap Research

May 20, 2015

Brian Marckx, CFA
bmarckx@zacks.com
Ph (312) 265-9474

scr.zacks.com 111 North Canal Street, Chicago, IL 60606

CytoSorbents Cp (CTSO- NASDAQ)

CTSO: Correction to our May 15th report

MERRIMAN CAPITAL

CytoSorbents Corporation (CTSO) **Buy**

CTSO Update Post Completion Of Quiet Period

Andrew D'Silva, Analyst (415) 568-3927 adsilva@merrimanco.com January 19, 2015

Key Metrics **Investment Conclusion**
CytoSorbents (CTSO) has developed a potentially breakthrough technology to extract

WBB Securities, LLC

Stephen G. Brozak • sbrozak@wbbsec.com • (908) 518-7610

INITIATING COVERAGE – FEBRUARY 25, 2015

CytoSorbents Corporation (NasdaqCM: CTSO)

Initiating Coverage with a Speculative Buy Rating and One-Year Price Target of \$13.00

12 Month Target Price	\$13.00
-----------------------	---------

Build Momentum in Key Media



+ MASS DEVICE

CytoSorbents inks deal with Fresenius Medical Care [\(link\)](#)
 By Mark Hollmer
 Mass Device
 December 16, 2014

Fresenius Medical Care is slated to distribute CytoSorbents' cytokine blood purification filters in several countries as part of a new strategic partnership.

CytoSorbents (OTC:CTSO) said yesterday that it scored an international strategic partnership with Fresenius (NYSE:FMS) that will boost access to international markets for its cytokine blood purification

Cardiovascular News

CytoSorbents submits IDE application for US CytoSorb cardiac surgery trial [\(link\)](#)
 By Dawn Powell
 Cardiovascular News
 January 2, 2014

MICROCAP DAILY

Cytosorbents Corp (NASDAQ:CTSO) Rebounding on a Stronger Note [\(link\)](#)
 By James Elliot
 MicroCap Daily
 December 30, 2014

Cytosorbents Corp (NASDAQ:CTSO) is coming back strong after a shack to just over \$9 a share. The stock has been upwards on huge strength in recent days hitting a high of \$12.86. The ticks

FierceMedical Devices

CytoSorbents To Advance HemoDefend Towards Commercialization with \$1.5 Million Phase II SBIR Contract from NHLBI/NIH

October 27, 2015

FDANEWS

Simplifying Global Compliance

CytoSorbents Files IDE for CytoSorb Cardiac Surgery Trial [\(link\)](#)
 By Kellen Owings
 FDANews
 January 2, 2015

BioCentury

CytoSorbents
 By Staff
 BioCentury
 December 24, 2014

FierceDrugDelivery

CytoSorbents no longer an OTC stock, uplists to Nasdaq [\(link\)](#)
 By Varun Saxena
 FierceDrugDelivery
 December 24, 2014

Starting today, CytoSorbents, maker of the CytoSorb extracorporeal cytokine adsorber to reduce inflammation in critically ill and cardiac surgery patients, will begin trading on the Nasdaq Capital Market instead of the over-the-counter market. Recent developments at the company include a partnership with dialysis magnate Fresenius Medical Care to help commercialize and distribute the product. "As we continue to advance our business through the ongoing commercial ramp of CytoSorb in 28 countries

ation to the FDA
 use of a heart-
 mmatory agents



CytoSorbents

Working to Save Lives Through Blood Purification

CytoSorbents Investment Summary

CytoSorbents is a hybrid: Combines the greater visibility and lower risk of a medical device company with product sales with the upside potential of a biotech

- Massive untapped \$20 billion unmet, medical need in critical care
- Generating significant CytoSorb[®] sales growth with 60+% gross margins
- Fueling growth through increased usage, clinical data, and continued geographic expansion
- Two pathways to CytoSorb[®] FDA approval : Cardiac Surgery and critical illnesses
- Expansion of existing strategic partnerships and addition of new partners

CytoSorb is helping to save lives throughout the world



***Providing Hope
in a helpless situation***



HELPING PATIENTS SURVIVE CRITICAL ILLNESSES WORLDWIDE



CytoSorbents™

Working to Save Lives Through Blood Purification

NASDAQ: CTSO

Dr. Phillip Chan, MD, PhD – CEO

pchan@cytosorbents.com